765880-61-3

Basic information

• Product Name: 6-CHLORO-CHROMAN-4-YLAMINE
• Synonyms: 6-CHLORO-CHROMAN-4-YLAMINE;2H-1-Benzopyran-4-amine, 6-chloro-3,4-dihydro-;6-chloro-3,4-dihydro-2H-chroMen-4-aMine;6-ChlorochroMan-4-aMine
• CAS NO: 765880-61-3
• Molecular Formula: C₉H₁₀ClNO
• Molecular Weight: 183.63
• EINECS: 604-604-1
• Mol File: 765880-61-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 268.9°C at 760 mmHg
• Flash Point: 116.4°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 0.00748mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 6-CHLORO-CHROMAN-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-CHROMAN-4-YLAMINE(765880-61-3)
• EPA Substance Registry System: 6-CHLORO-CHROMAN-4-YLAMINE(765880-61-3)

Safety Data

• Hazardous Substances Data: 765880-61-3(Hazardous Substances Data)

Usage

General Description

6-Chloro-chroman-4-ylamine is a chemical compound with the formula C9H9ClNO. It is a derivative of chroman and belongs to the class of organic compounds known as indoles and derivatives. 6-CHLORO-CHROMAN-4-YLAMINE is commonly used in the production of pharmaceuticals, specifically in the synthesis of potential drug candidates for various medical applications. It has also been studied for its potential biological activities, including its anti-inflammatory and antimicrobial properties. Additionally, 6-chloro-chroman-4-ylamine has been investigated for its potential role in the treatment of neurological disorders and cancer. Overall, this chemical compound has shown promise in various research areas and may have potential applications in the pharmaceutical industry.

InChI:InChI=1/C9H10ClNO/c10-6-1-2-9-7(5-6)8(11)3-4-12-9/h1-2,5,8H,3-4,11H2

Upstream product

• 37674-72-9 6-chloro-chroman-4-one 
• 147592-12-9 6-chloro-chroman-4-ol 
• 3284-79-5 3-(4-chlorophenoxy)propionic acid 
• 106-48-9 4-chloro-phenol 

Downstream Products

• 1394153-58-2 N-[6-chlorochroman-4-yl]-N'-(3-nitrophenyl)thiourea 
• 1394153-57-1 N-[6-chlorochroman-4-yl]-N'-(4-nitrophenyl)thiourea 

Relevant articles and documents

N-Aryl-N'-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure-activity relationship analysis

A series of chroman derivatives previously reported as potassium channel openers, as well as some newly synthesized simplified structures, were examined for their in vitro effects on the growth of three human high-grade glioma cell lines: U373, T98G, and Hs683. Significant in vitro growth inhibitory activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the corresponding phenylthioureas. No significant differences were observed in terms of chroman-derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli (Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli (U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow cytometry analyses confirmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase. Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects, while 3e displayed cytotoxic ones. As a result, this work identified phenylurea-type 2,2-dimethylchromans as a new class of antitumor agents to be further explored for an innovative therapeutic approach for high-grade glioma and/or for a possible new mechanism of action.

8-SUBSTITUTED 2-(BENZIMIDAZOLYL)PURINE DERIVATIVES FOR IMMUNOSUPPRESSION

The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formula I: